Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...

Alumis and Acelyrin have filed a definitive proxy statement/prospectus with the US Securities and Exchange Commission for the ...

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Wall Street on Friday suffered its biggest weekly retreat since the peak of the COVID-19 pandemic collapse in 2020. The panic ...

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Potential Alumis Inc. (NASDAQ:ALMS) shareholders may wish to note that the Independent Director, Alan Colowick, recently bought US$130k worth of stock, paying US$7.04 for each share. Although the ...

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be comple ...

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be comple ...

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be ...

Shares of Simulations Plus, Inc. SLP rose sharply during Friday's session as the company posted stronger-than-expected ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...